This inventor holds 0 USPTO granted patents, plus 1 CIPO patent.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Title: Lin Rong-Hwa: Innovator in Immune Response Modulation
Introduction
Lin Rong-Hwa is a notable inventor based in Taiwan. He has made significant contributions to the field of immunology, particularly in the development of compounds that target P-Selectin Glycoprotein Ligand 1 (PSGL-1). His work focuses on controlling immune responses, which can be crucial in managing various medical conditions.
Latest Patents
Lin Rong-Hwa holds a patent for "Modulators Of P-Selectin Glycoprotein Ligand 1." This invention involves compounds that bind to PSGL-1 on the surface of T cells or natural killer (NK) cells. These compounds can induce T cell or NK cell depletion and apoptosis. The methods described in the patent can be utilized to control unwanted immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases. He currently has 0 patents.
Career Highlights
Lin Rong-Hwa is associated with Abgenomics Cooperatief U.A., where he continues to advance his research in immunology. His work is pivotal in the development of therapies aimed at modulating immune responses.
Collaborations
Lin collaborates with notable colleagues, including Wu Chung-Hsiun and Hsu Pei-Ling. Their combined expertise contributes to the innovative research being conducted at Abgenomics.
Conclusion
Lin Rong-Hwa is a key figure in the field of immune response modulation, with a focus on developing therapeutic compounds for critical health issues. His contributions are essential for advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile